MMP9 and cancer: Tested treatments resulted in a significant decrease in the relative expression of MMP-9 ranging from 0.9 to 0.1 fold in HepG2 cancer treated cells (Fig. 6B); the most pronounced effect was recorded in case of sorafenib-ramucirumab combination (0.1 fold).